Downgrade Warning
S&P affirms negative outlook on India, says chances of downgrade remain
Ratings agency Standard & Poor's affirmed India's sovereign rating at "BBB-minus" with a "negative" outlook, reiterating there was a one-in-three chance of a ratings downgrade over the next 12 months, a statement said on Friday. Full Article
REUTERS SHOWCASE
Revitalising China
China president takes charge of sweeping economic reform plans - sources. Full Article
Buy, Sell or Hold?
Confused while buying stocks? Get buy, sell or hold recommendations from VantageTrade. Full Coverage
Reuters India Mobile
Get the latest news on the go. Visit Reuters India on your mobile device. Full Coverage
Piramal Group's PE to raise $185 mln in new fund
MUMBAI |
MUMBAI (Reuters) - IndiaVenture Advisors, a private equity fund owned by Indian drugmaker Piramal Enterprises, is planning to raise up to 10 billion rupees for a new fund that will invest in healthcare and education, its chairman said.
Investors have stepped up ploughing money into the healthcare sector in India, home to more than 1.2 billion people, betting on steadier returns than in other businesses that have been hit by an economic slowdown.
"It's a defensive sector and is recession-proof," IndiaVenture Chairman A.K. Purwar told Reuters. "On top of that, we have our parent group's strength to leverage and do better value addition."
IndiaVenture currently manages about 3.7 billion rupees.
Private equity investments in Indian healthcare have nearly quadrupled to $520.36 million so far this year from $137.41 million in the same period a year ago, according to Thomson Reuters data.
In comparison, private equity investments across all sectors in India have fallen 17.5 percent to $3.26 billion from $3.95 billion during the same period last year, the data showed.
"We are about to start formal marketing of the fund," said Purwar, a former chairman of top lender State Bank of India.
The bulk of the fund would be raised from India, while global investors would be tapped for about 20 percent, he said.
Piramal Enterprises, controlled by billionaire Ajay Piramal, is one of India's leading healthcare firms. It sold its India formulations business to U.S.-based Abbott Laboratories for $3.7 billion in 2010.
(Editing by Ranjit Gangadharan)
- Tweet this
- Link this
- Share this
- Digg this
- Reprints






Follow Reuters